Solvonis Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	0.59	0.54	0.38
Revenue Growth (YoY)	-	-	8.30%	44.37%	13.77%
Cost of Revenue	-	-	0.45	0.24	0.2
Gross Profit	-	-	0.14	0.3	0.17
Selling, General & Admin	3.02	1.51	2.36	2.91	1.71
Other Operating Expenses	-	-	-	-0.02	-0
Operating Expenses	3.58	1.51	2.54	3	1.79
Operating Income	-3.58	-1.51	-2.4	-2.7	-1.62
Interest Expense	-	-0.06	-0	-0	-0.01
Currency Exchange Gain (Loss)	0.1	-	-	-	-
EBT Excluding Unusual Items	-3.48	-1.57	-2.4	-2.71	-1.64
Gain (Loss) on Sale of Assets	-	0.13	-	-	-
Asset Writedown	-2.26	-	-0.72	-	-
Pretax Income	-5.74	-1.45	-3.12	-2.71	-1.64
Earnings From Continuing Operations	-5.74	-1.45	-3.12	-2.71	-1.64
Earnings From Discontinued Operations	-	-0.14	-	-	-
Net Income	-5.74	-1.59	-3.12	-2.71	-1.64
Net Income to Common	-5.74	-1.59	-3.12	-2.71	-1.64
Shares Outstanding (Basic)	4,783	1,157	104	104	70
Shares Outstanding (Diluted)	4,783	1,157	104	104	70
Shares Change (YoY)	313.52%	1011.63%	0.45%	47.98%	2.94%
EPS (Basic)	-0.00	-0.00	-0.03	-0.03	-0.02
EPS (Diluted)	-0.00	-0.00	-0.03	-0.03	-0.02
Free Cash Flow	-3.27	-1.13	-1.45	-3.08	-0.44
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.03	-0.01
Gross Margin	-	-	24.02%	55.35%	46.12%
Operating Margin	-	-	-408.18%	-498.34%	-431.96%
Profit Margin	-	-	-531.52%	-499.08%	-435.62%
Free Cash Flow Margin	-	-	-247.70%	-567.90%	-116.44%
EBITDA	-	-1.34	-2.23	-2.59	-1.54
D&A For EBITDA	-	0.17	0.17	0.11	0.08
EBIT	-3.58	-1.51	-2.4	-2.7	-1.62

Source: S&P Global Market Intelligence. Standard template. Financial Sources.